Products from BPS Bioscience require a minimum order value above 400€
Encompassing Amino Acids: 109-270
Application: Useful for binding studies.
Assay Conditions: A 96-well plate was coated with IL-33, His-Avi-Tag Recombinant (100 ng/well in PBS) at 4°C overnight. The plate was washed three times with PBST, and 200 µl Blocking Buffer 3 was added for 2 hours at Room Temperature (RT). After three washes in PBST, a 1:2 serial dilution of IL-33 protein prepared in PP-02 Assay Buffer (#82620), was added and incubated at RT for 1 hour. The plate was washed three times and incubated with anti-His-HRP conjugate diluted of 1:2000 in Blocking Buffer 3 for 1 hour at RT. After three washes, 100 µl of ELISA ECL Substrate (#79670) was added to each well and chemiluminescence was measured.
Background: IL-33 is a cytokine of the IL-1 family that is released in response to external triggers such as trauma, allergen exposure, and infections. IL-33 exists in a reduced or oxidized state, which trigger different signaling pathways. When in its reduced state (IL-33red) it binds to IL-1RL1 ((interleukin 1 receptor like 1), also named IL-33R or ST2 (receptor serum-stimulated 2). IL-1RL1 exists as both a membrane bound protein or a truncated soluble form. Binding of IL-33 to IL-1RL1 initiates a signaling pathway that involves NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and MAPK (mitogen-activated protein kinase), and results in release of pro-inflammatory cytokines and chemokines. The soluble form of IL-1RL1 can act as a decoy receptor for IL-33. Dysregulation in the levels of IL-33 is implicated in the pathology of inflammatory and infectious diseases, including COVID-19, COPD (chronic obstructive pulmonary disease), and asthma. The involvement of IL-33 in these diseases has made it a high value therapeutic target, with strategies such as antibodies being developed to inhibit the binding of IL-33 to its receptor. One example is tozorakimab (MEDI3506), currently being evaluated as treatment for COPD. Further studies on IL-33 and its receptor will likely result in new therapies for IL-33 related disorders.
Description: Recombinant human IL-33 (Interleukin 33), encompassing amino acids 109-270. This construct contains an N-terminal His-tag (6xHis) followed by an Avi-Tag™. The recombinant protein was affinity purified.
Endotoxin Level: 99.6 EU/mg
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol.
Genbank: NM_033439.4
Purity: ≥80%
Storage Stability: >6 months at –80°C.
Tags: His-Avi
Target: IL-33
Uniprot: O95760
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
English
Deutsch
